These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 25425638)

  • 1. Development of Severe Anemia and Changes in Hemoglobin in a Cohort of HIV-Infected Ugandan Adults Receiving Zidovudine-, Stavudine-, and Tenofovir-Containing Antiretroviral Regimens.
    Parkes-Ratanshi R; Katende D; Levin J; Wakeham K; Heiner G; Kamali A; Lalloo DG
    J Int Assoc Provid AIDS Care; 2015; 14(5):455-62. PubMed ID: 25425638
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early upper digestive tract side effects of zidovudine with tenofovir plus emtricitabine in West African adults with high CD4 counts.
    Ouattara E; Danel C; Moh R; Gabillard D; Peytavin G; Konan R; Carrou JL; Bohoussou F; Eholie SP; Anglaret X
    J Int AIDS Soc; 2013 Apr; 16(1):18059. PubMed ID: 23639243
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of adipokine expression and mitochondrial toxicity in HIV patients with lipoatrophy on stavudine- and zidovudine-containing regimens.
    Jones SP; Qazi N; Morelese J; Lebrecht D; Sutinen J; Yki-Jărvinen H; Back DJ; Pirmohamed M; Gazzard BG; Walker UA; Moyle GJ
    J Acquir Immune Defic Syndr; 2005 Dec; 40(5):565-72. PubMed ID: 16284533
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An open randomized controlled trial of zidovudine plus lamivudine versus stavudine plus lamivudine.
    Foudraine NA; de Jong JJ; Jan Weverling G; van Benthem BH; Maas J; Keet IP; Jurriaans S; Roos MT; Vandermeulen K; de Wolf F; Lange JM
    AIDS; 1998 Aug; 12(12):1513-9. PubMed ID: 9727573
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized, open-label study of the safety and efficacy of switching stavudine or zidovudine to tenofovir disoproxil fumarate in HIV-1-infected children with virologic suppression.
    Saez-Llorens X; Castaño E; Rathore M; Church J; Deville J; Gaur A; Estripeaut D; White K; Arterburn S; Enejosa JV; Cheng AK; Chuck SL; Rhee MS
    Pediatr Infect Dis J; 2015 Apr; 34(4):376-82. PubMed ID: 25760565
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High incidence of zidovudine induced anaemia in HIV infected patients in eastern India.
    Agarwal D; Chakravarty J; Chaube L; Rai M; Agrawal NR; Sundar S
    Indian J Med Res; 2010 Oct; 132():386-9. PubMed ID: 20966515
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Response to zidovudine/didanosine-containing combination antiretroviral therapy among HIV-1 subtype C-infected adults in Botswana: two-year outcomes from a randomized clinical trial.
    Bussmann H; Wester CW; Thomas A; Novitsky V; Okezie R; Muzenda T; Gaolathe T; Ndwapi N; Mawoko N; Widenfelt E; Moyo S; Musonda R; Mine M; Makhema J; Moffat H; Essex M; Degruttola V; Marlink RG
    J Acquir Immune Defic Syndr; 2009 May; 51(1):37-46. PubMed ID: 19282782
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparison of stavudine, didanosine and indinavir with zidovudine, lamivudine and indinavir for the initial treatment of HIV-1 infected individuals: selection of thymidine analog regimen therapy (START II).
    Eron JJ; Murphy RL; Peterson D; Pottage J; Parenti DM; Jemsek J; Swindells S; Sepulveda G; Bellos N; Rashbaum BC; Esinhart J; Schoellkopf N; Grosso R; Stevens M
    AIDS; 2000 Jul; 14(11):1601-10. PubMed ID: 10983647
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparison of stavudine plus lamivudine versus zidovudine plus lamivudine in combination with indinavir in antiretroviral naive individuals with HIV infection: selection of thymidine analog regimen therapy (START I).
    Squires KE; Gulick R; Tebas P; Santana J; Mulanovich V; Clark R; Yangco B; Marlowe SI; Wright D; Cohen C; Cooley T; Mauney J; Uffelman K; Schoellkopf N; Grosso R; Stevens M
    AIDS; 2000 Jul; 14(11):1591-600. PubMed ID: 10983646
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anemia among HIV Infected Individuals Taking ART with and without Zidovudine at Addis Ababa, Ethiopia.
    Tamir Z; Alemu J; Tsegaye A
    Ethiop J Health Sci; 2018 Jan; 28(1):73-82. PubMed ID: 29622909
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased incidence of symptomatic peripheral neuropathy among adults receiving stavudine- versus zidovudine-based antiretroviral regimens in Kenya.
    McGrath CJ; Njoroge J; John-Stewart GC; Kohler PK; Benki-Nugent SF; Thiga JW; Etyang A; Chung MH
    J Neurovirol; 2012 Jun; 18(3):200-4. PubMed ID: 22528481
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Tenofovir as a strategy to avoid or limit adverse effects].
    Portilla J
    Enferm Infecc Microbiol Clin; 2008 Jun; 26 Suppl 8():19-24. PubMed ID: 19195434
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anaemia and zidovudine-containing antiretroviral therapy in paediatric antiretroviral programmes in the IeDEA Paediatric West African Database to evaluate AIDS.
    Renner LA; Dicko F; Kouéta F; Malateste K; Gueye RD; Aka E; Eboua TK; Azondékon A; Okomo U; Touré P; Ekouévi D; Leroy V;
    J Int AIDS Soc; 2013 Sep; 16(1):18024. PubMed ID: 24047928
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence of anaemia in HIV-infected children at the University of Abuja Teaching Hospital, Gwagwalada.
    Okechukwu AA; Gambo D; Okechukwu IO
    Niger J Med; 2010; 19(1):50-7. PubMed ID: 20232757
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The use of a triple nucleoside-nucleotide regimen for nonoccupational HIV post-exposure prophylaxis.
    Winston A; McAllister J; Amin J; Cooper DA; Carr A
    HIV Med; 2005 May; 6(3):191-7. PubMed ID: 15876286
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tenofovir or zidovudine in three-drug combination therapy with one nucleoside reverse transcriptase inhibitor and one non-nucleoside reverse transcriptase inhibitor for initial treatment of HIV infection in antiretroviral-naïve individuals.
    Spaulding A; Rutherford GW; Siegfried N
    Cochrane Database Syst Rev; 2010 Oct; (10):CD008740. PubMed ID: 20927777
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost and cost-effectiveness of switching from d4T or AZT to a TDF-based first-line regimen in a resource-limited setting in rural Lesotho.
    Jouquet G; Bygrave H; Kranzer K; Ford N; Gadot L; Lee J; Hilderbrand K; Goemaere E; Vlahakis N; Trivino L; Makakole L; Cleary S
    J Acquir Immune Defic Syndr; 2011 Nov; 58(3):e68-74. PubMed ID: 21765366
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of incidence of zidovudine induced anemia in Indian human immunodeficiency virus positive patients in comparison with stavudine based highly active antiretroviral therapy.
    Rajesh R; Vidyasagar S; Varma DM; Mohiuddin S; Noorunnisa
    Int J Risk Saf Med; 2011; 23(3):171-80. PubMed ID: 22020397
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of tenofovir, zidovudine, or stavudine as part of first-line antiretroviral therapy in a resource-limited-setting: a cohort study.
    Velen K; Lewis JJ; Charalambous S; Grant AD; Churchyard GJ; Hoffmann CJ
    PLoS One; 2013; 8(5):e64459. PubMed ID: 23691224
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HIV-1 drug resistance testing is essential for heavily-treated patients switching from first- to second-line regimens in resource-limited settings: evidence from routine clinical practice in Cameroon.
    Takou D; Fokam J; Teto G; Santoro MM; Ceccherini-Silberstein F; Nanfack AJ; Sosso SM; Dambaya B; Salpini R; Billong SC; Gori C; Fokunang CN; Cappelli G; Colizzi V; Perno CF; Ndjolo A
    BMC Infect Dis; 2019 Mar; 19(1):246. PubMed ID: 30871487
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.